Enzolytics Inc. (OTC:ENZC) Stock Is In Focus After Multiple News
There are a number of companies that came on the radar of investors yesterday, and it could be a good idea for investors to consider taking a closer look at a few of those. A company that could be worth tracking today could be Enzolytics Inc. (OTCMKTS:ENZC).
The stock came into focus among investors on Tuesday after the company’s fully owned subsidiary unit, Biogenysis Inc., a drug development biotechnology entity, made a key announcement. The subsidiary announced that it had entered into a partnership with Estonia-based Contenta Ltd. and Khalpey AI Lab on a project for identifying biomarkers associated with the early onset of Alzheimer’s disease. It was a significant announcement considering the fact that the identification of such biomarkers could help in the development of preventive therapies for providing treatment, which could halt the spread of Alzheimer’s at the early stages.
The market for such a product could also be significant. The condition afflicts more than 6 million people in the United States alone and takes a massive toll on the economy. In 2022 alone, it cost $321 billion, and the bills for unpaid caregiving stood at $271 billion. The problem, unfortunately, is only expected to get worse. As per reliable estimates, the number of people suffering from Alzheimer’s is expected to go up by more than 100% to as many as 12.7 million by 2050.
Once that figure is reached, the annual costs will hit a staggering $1 trillion. It ought to be noted that the rates of treatment and diagnosis are low for all the different stages of the condition. Hence, the possibility of developing accurate diagnostic tests that could identify early-onset biomarkers could prove vital. The artificial intelligence-powered analysis of the biomarkers could provide unique solutions to the issue. Biogenysis already holds considerable expertise in the field and would also activate its contacts to explore the opportunity more closely. The partnership between the three parties would help in combining the different specialties in efforts to come up with a solution.
The subsidiary announced on August 24 that there had been progress in its application for the Patent Cooperation Treaty (PCT) pertaining to Biogenysis’ anti-SARS-CoV-2 monoclonal antibodies invention. It was noted at the time that the application had been advanced to the stage of a United States National Stage Application at the United States Patent Office.
Additionally, a formal application had also been made with the European Patent Organization (EPO). The application with the EPO would provide the invention with coverage in as many as 39 nations that are under the purview of the organization. The 39 nations include the entirety of the European Union, the United Kingdom, and some other nations in Europe and nearby regions. The pending applications for Biogenysis had as many as 23 distinct patent claims, as per the new release.
The company had deployed artificial intelligence to discover 19 immutable conserved virus sites on the COVID-19 virus. These sites, which it discovered, were patentable.
